Herzog R, Leuschner J
Henning Berlin GmbHa, Fed. Rep. of Germany.
Arzneimittelforschung. 1994 Dec;44(12):1362-5.
The 26-week oral toxicity of benzalazine (2-hydroxy-5-[(4-carboxyphenyl) azo]benzoic acid, CAS 64896-26-0), a new agent for the treatment of ulcerative colitis and Crohn's disease of the large intestine, was investigated in beagle dogs of both sexes. No change was observed in the 160 mg/kg group. A reduction of the aspartate aminotransferase activity was observed from 800 mg/kg b.w./d onwards. In high-dosed dogs (1600 mg/kg b.w./d) liver weights were increased and substance-related neutral fat disposition in liver cells was observed. The non-toxic dose was 160 mg/kg b.w./d under these experimental conditions.
对一种用于治疗溃疡性结肠炎和大肠克罗恩病的新药苄拉嗪（2-羟基-5-[(4-羧基苯基)偶氮]苯甲酸，CAS 64896-26-0）进行了为期26周的口服毒性研究，实验对象为雌雄比格犬。160mg/kg组未观察到变化。从800mg/kg体重/天起，观察到天冬氨酸转氨酶活性降低。在高剂量组犬（1600mg/kg体重/天）中，肝脏重量增加，观察到肝细胞内与物质相关的中性脂肪沉积。在这些实验条件下，无毒剂量为160mg/kg体重/天。
